Skip to main content
ScholarsBetaWeill Cornell Medicine

Highlights

  1. 1
    Molecular oncology · 2022
    ASAlexandros SigarasLGLorraine GudasSTScott T. TagawaDMDavid M Nanus+6 more →AMAna M. Molina
    PMID: 35231161PMCID: PMC9208073DOISenior author10 citations
  2. 2
    Investigational new drugs · 2020
    AMAna M. MolinaPJPaul J ChristosDMDavid M NanusSTScott T. TagawaLGLorraine Gudas
    PMID: 31898184DOIFirst author17 citations

Publications

79 publications

Clinical research

5 studies
Completed & closed trials (5)
  • PI
    Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies
    PHASE2 · Bristol-Myers Squibb Company · IRB STUDY CLOSURE (as of 2024)
    Cancer
    NCT03899155
  • PI
    PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
    PHASE3 · Alliance for Clinical Trials in Oncology · CLOSED TO ACCRUAL (as of 2024)
    Clear Cell Renal Cell Carcinoma; Metastatic Malignant Neoplasm in the Bone; Metastatic Malignant Neoplasm in the Lymph Nodes; Metastatic Malignant Neoplasm in the Soft Tissue; Metastatic Malignant Neoplasm in the Viscera; Rhabdoid Tumor of the Kidney; Sarcomatoid Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8
    NCT03793166
  • PI
    A Single Arm, Multicenter, Phase 2 Trial to Evaluate the Efficacy of Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)
    PHASE2 · The Washington University (dba Washington University School of Medicine) · IRB STUDY CLOSURE (as of 2024)
    Renal Cell Carcinoma
    NCT04267120
  • PI
    A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis (RadiCal)
    PHASE2 · Alliance for Clinical Trials in Oncology · CLOSED TO ACCRUAL (as of 2023)
    Advanced Renal Cell Carcinoma; Chromophobe Renal Cell Carcinoma; Clear Cell Renal Cell Carcinoma; Collecting Duct Carcinoma; Kidney Medullary Carcinoma; Metastatic Malignant Neoplasm in the Bone; Papillary Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v8; Unclassified Renal Cell Carcinoma
    NCT04071223
  • PI
    Phase II Randomized Double Blind Trial of PF-04518600, an OX40 Antibody, in Combination With Axitinib Versus Axitinib in Immune-Checkpoint Inhibitor Exposed Patients With Metastatic Renal Cell Carcinoma
    PHASE2 · USC Keck School of Medicine Norris Cancer Center · CLOSED TO ACCRUAL (as of 2021)
    Clear Cell Renal Cell Carcinoma; Metastatic Renal Cell Cancer; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer
    NCT03092856